Researchers have also discovered that treating mice with antisense oligonucleotides targeting the PNPLA3 gene suppressed the expression of the PNPLA3 I148M variant, slowed the progression of NAFLD, and improved liver fibrosis [24]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.